Revvity Inc stock hits 52-week high at 130.07 USD

Revvity shares hit a 52-week high at $130.07, up 45.8% over the past year, after Q2 results beat expectations with adjusted EPS of $1.41 vs $1.21 (+16.5%) on revenue of $729.68M vs $703.39M (+3.7%). The beat was driven by stronger organic growth, wider margins, and AI-linked demand, with $16M from tariff refunds and tax savings boosting results. Stifel lifted its price target to $110 (from $100) but kept a Hold, and the stock slipped in premarket—suggesting some investor caution around the quality of the upside.

Analysis

RVTY’s move reads more like a quality-of-earnings problem than a fundamental breakout. When a healthcare tools name is already above most published targets and the latest upside comes partly from non-recurring tax/tariff items, the market is paying for a margin story that may not be repeatable. That leaves the stock vulnerable if sell-side models lift EPS faster than core demand actually converts into sustained operating leverage.

The second-order read-through is to the broader tools/diagnostics complex: if the “AI demand” narrative is real, the best beneficiaries are the vendors that sell picks-and-shovels workflow automation, not the companies with the cleanest PR around it. TMO, DHR, and WAT should outperform RVTY if this is a genuine capex cycle, because they have deeper installed bases and more pricing power; if it’s just inventory normalization, RVTY’s relative multiple should compress first.

Near term, momentum buyers can keep the tape elevated for a few sessions, but the key catalyst is the next guide update and whether gross margin holds without one-time support. Over 6-18 months, the risk is multiple contraction if growth settles into low-single digits while the stock is priced like a premium compounder. The contrarian view is that the market may be over-penalizing the company’s mix shift and underestimating the persistence of automation demand—but that needs proof in recurring organic growth, not headline EPS beats.

Key Decisions for Investors

• Fade strength in RVTY on any push back toward the 52-week high area; use a 1-3 month short thesis with a stop only if management reiterates/raises guidance on clearly recurring operating improvement.
• Pair trade: short RVTY / long TMO or DHR over the next 1-3 months to express relative multiple compression if healthcare tools sentiment stays constructive but quality disperses.
• Consider a bearish option structure on RVTY (put spread rather than naked puts) into the next catalyst window; the trade works if the stock merely mean-reverts to pre-earnings levels, not if it collapses.
• Watch for the next quarter’s organic growth and gross margin bridge; if the company can repeat the beat without tariff refunds/tax help, cover the short thesis quickly because the market will re-rate the stock upward.
• Alert level: a sustained break above the current high on heavy volume would invalidate the fade-the-rally setup and suggest the market is willing to capitalize the AI/automation narrative more aggressively than expected.